Results 1 to 10 of about 75,890 (310)

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer [PDF]

Case Reports in Oncology, 2014
The prognosis of patients with locally advanced pancreatic cancer can be improved if secondary complete (R0) resection is possible. In patients initially staged as unresectable this may be achieved with neoadjuvant treatment which is usually ...
Volker Kunzmann, Ken Herrmann, Christina Bluemel, Markus Kapp, Ingo Hartlapp, Ulrich Steger   +5 more
doaj   +7 more sources

Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer [PDF]

Clinical and Experimental Gastroenterology
Shane S Neibart,1 Shalini Moningi,1 Krishan R Jethwa2 1Department of Radiation Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, MA, USA; 2Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USACorrespondence: Shalini
Neibart SS, Moningi S, Jethwa KR
doaj   +2 more sources

Geographic variation in attitudes regarding management of locally advanced pancreatic cancer

Surgery Open Science, 2022
Background: Recent literature suggests wide variations exist in the international management of locally advanced pancreatic cancer. This study sought to evaluate how geography contributes to variations in management of locally advanced pancreatic cancer.
Logan R. McNeil, BA, Alex B. Blair, MD, Robert W. Krell, MD, Chunmeng Zhang, MD, Aslam Ejaz, MD, MPH, Vincent P. Groot, MD, PhD, Georgios Gemenetzis, MD, James C. Padussis, MD, Massimo Falconi, MD, Christopher L. Wolfgang, MD, PhD, Matthew J. Weiss, MD, Chandrakanth Are, MD, MBA, Jin He, MD, PhD, Bradley N. Reames, MD, MS   +13 more
doaj   +1 more source

Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma—A Critical Review of Randomised Trials

Current Oncology, 2023
Pancreatic cancer is rising as one of the leading causes of cancer-related death worldwide. Patients often present with advanced disease, limiting curative treatment options and therefore making management of the disease difficult.
Mathilde Weisz Ejlsmark, Tine Schytte, Uffe Bernchou, Rana Bahij, Britta Weber, Michael Bau Mortensen, Per Pfeiffer   +6 more
doaj   +1 more source

The evolving role of radiation in pancreatic cancer

Frontiers in Oncology, 2023
Pancreatic cancer is the fourth leading cause of cancer mortality in the United States. Chemotherapy in resectable pancreatic cancer has improved survival by 10-20%.
Midhun Malla, Fatemeh Fekrmandi, Nadia Malik, Hassan Hatoum, Sagila George, Richard M. Goldberg, Sarbajit Mukherjee   +6 more
doaj   +1 more source

Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX

Frontiers in Oncology, 2022
BackgroundThe complete resection rate of pancreatic cancer has increased because of the advent of efficacious first-line treatments for unresectable pancreatic cancer.
Jin Ho Choi, Min Kyu Kim, Sang Hyub Lee, Jin Woo Park, Namyoung Park, In Rae Cho, Ji Kon Ryu, Yong-Tae Kim, Jin-Young Jang, Wooil Kwon, Hongbeom Kim, Woo Hyun Paik   +11 more
doaj   +1 more source

Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis

BMC Gastroenterology, 2023
Background The role of chemoradiotherapy in unresectable locally advanced pancreatic cancer is still unclear. Methods Data from patients with unresectable locally advanced pancreatic cancer were extracted from the Surveillance, Epidemiology, and End ...
Zi-Meng Wang, Hong-Bin Ma, Yan Meng
doaj   +1 more source

Long-term survival after esophagectomy with distal pancreatectomy for locally advanced esophageal cancer with pancreatic invasion: a case report

Surgical Case Reports, 2021
Background The treatment for the locally advanced esophageal cancer invading adjacent organs is controversial. We performed a radical surgery for a patient suffering from lower esophageal cancer with pancreatic invasion, and led to long-term survival ...
Yoshiki Kaneko, Katsuji Hisakura, Koichi Ogawa, Yoshimasa Akashi, Yusuke Ohara, Yohei Owada, Tsuyoshi Enomoto, Kinji Furuya, Shoko Moue, Manami Doi, Kazuhiro Takahashi, Osamu Shimomura, Shinji Hashimoto, Noriaki Sakamoto, Tsunehiko Maruyama, Tatsuya Oda   +15 more
doaj   +1 more source

Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial)

BMC Cancer, 2023
Background Locally advanced pancreatic ductal adenocarcinoma (PDAC), accounting for about 30% of PDAC patients, is difficult to cure by radical resection or systemic chemotherapy alone.
Osamu Shimomura, Masato Endo, Hirokazu Makishima, Takeshi Yamada, Shinji Hashimoto, Haruko Numajiri, Yoshihiro Miyazaki, Manami Doi, Kinji Furuya, Kazuhiro Takahashi, Toshikazu Moriwaki, Naoyuki Hasegawa, Yoshiyuki Yamamoto, Yusuke Niisato, Mariko Kobayashi, Masashi Mizumoto, Kei Nakai, Takashi Saito, Sodai Hoshiai, Tsukasa Saida, Bryan J. Mathis, Kensaku Mori, Takahito Nakajima, Kiichiro Tsuchiya, Hideyuki Sakurai, Tatsuya Oda   +25 more
doaj   +1 more source

Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial

Clinical and Translational Radiation Oncology, 2022
Purpose: Addressing the epidermal growth factor receptor (EGFR)-pathway by the competitive receptor ligand cetuximab is a promising strategy in pancreatic cancer.
Jakob Liermann, Marc Munter, Patrick Naumann, Amir Abdollahi, Robert Krempien, Juergen Debus   +5 more
doaj   +1 more source